RXRX vs. MSFT

Last updated Jun 3, 2026

RXRX (Recursion Pharmaceuticals, Inc.) and MSFT (Microsoft Corporation) are both stocks. RXRX operates in Biotechnology (Healthcare), while MSFT operates in Software - Infrastructure (Technology). Over the past 5 years, RXRX returned -33.81%/yr vs 13.35%/yr for MSFT. At a 0.30 correlation, their price movements are largely independent.

Performance

RXRX vs. MSFT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Recursion Pharmaceuticals, Inc. (RXRX) and Microsoft Corporation (MSFT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, RXRX achieves a -11.74% return, which is significantly lower than MSFT's -8.34% return.

RXRX

• 1D: -4.75%
• 1M: 6.49%
• YTD: -11.74%
• 6M: -16.44%
• 1Y: -17.39%
• 3Y*: -24.02%
• 5Y*: -33.81%
• 10Y*: —

MSFT

• 1D: -4.17%
• 1M: 6.71%
• YTD: -8.34%
• 6M: -9.54%
• 1Y: -3.71%
• 3Y*: 10.44%
• 5Y*: 13.35%
• 10Y*: 25.43%

*Multi-year figures are annualized to reflect compound growth (CAGR)

RXRX vs. MSFT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RXRX Recursion Pharmaceuticals, Inc.	-11.74%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%
MSFT Microsoft Corporation	-8.34%	15.58%	12.93%	58.19%	-28.02%	29.77%

Correlation

The correlation between RXRX and MSFT is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.24
Correlation (5Y) Calculated over the trailing 5-year period	0.31
Correlation (All Time) Calculated using the full available price history since Apr 19, 2021	0.30

Fundamentals

Market Cap RXRX : $1.91B MSFT : $3.29T
EPS RXRX : -$1.17 MSFT : $16.79
PS Ratio RXRX : 26.15 MSFT : 10.34
PB Ratio RXRX : 1.86 MSFT : 7.93
Total Revenue (TTM) RXRX : $66.29M MSFT : $318.27B
Gross Profit (TTM) RXRX : -$22.83M MSFT : $217.41B
EBITDA (TTM) RXRX : -$505.90M MSFT : $200.96B

Return for Risk

RXRX vs. MSFT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXRX

RXRX Risk / Return Rank: 32
RXRX Sharpe Ratio Rank: 31
RXRX Sortino Ratio Rank: 33
RXRX Omega Ratio Rank: 32
RXRX Calmar Ratio Rank: 32
RXRX Martin Ratio Rank: 33

MSFT

MSFT Risk / Return Rank: 33
MSFT Sharpe Ratio Rank: 34
MSFT Sortino Ratio Rank: 28
MSFT Omega Ratio Rank: 29
MSFT Calmar Ratio Rank: 36
MSFT Martin Ratio Rank: 37

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RXRX vs. MSFT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Microsoft Corporation (MSFT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RXRX	MSFT	Difference
Sharpe ratio Return per unit of total volatility	-0.24	-0.15	-0.09
Sortino ratio Return per unit of downside risk	0.16	-0.04	+0.19
Omega ratio Gain probability vs. loss probability	1.02	1.00	+0.02
Calmar ratio Return relative to maximum drawdown	-0.23	-0.10	-0.13
Martin ratio Return relative to average drawdown	-0.39	-0.21	-0.18
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RXRX vs. MSFT - Sharpe Ratio Comparison

The current RXRX Sharpe Ratio is -0.24, which is lower than the MSFT Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of RXRX and MSFT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	RXRX	MSFT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.24	-0.15	-0.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.36	0.50	-0.87
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.94	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.37	0.75	-1.12

Drawdowns

RXRX vs. MSFT - Drawdown Comparison

The maximum RXRX drawdown since its inception was -93.13%, which is greater than MSFT's maximum drawdown of -69.38%. Use the drawdown chart below to compare losses from any high point for RXRX and MSFT.

Drawdown Indicators

	RXRX	MSFT	Difference
Max Drawdown Largest peak-to-trough decline	-93.13%	-69.38%	-23.75%
Max Drawdown (1Y) Largest decline over 1 year	-58.17%	-33.91%	-24.26%
Max Drawdown (3Y) Largest decline over 3 years	-82.09%	-33.91%	-48.18%
Max Drawdown (5Y) Largest decline over 5 years	-93.13%	-37.15%	-55.98%
Max Drawdown (10Y) Largest decline over 10 years	—	-37.15%	—
Current Drawdown Current decline from peak	-91.27%	-18.07%	-73.20%
Average Drawdown Average peak-to-trough decline	-75.33%	-21.78%	-53.55%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.04%	15.90%	+19.14%

Volatility

RXRX vs. MSFT - Volatility Comparison

Recursion Pharmaceuticals, Inc. (RXRX) has a higher volatility of 18.74% compared to Microsoft Corporation (MSFT) at 9.31%. This indicates that RXRX's price experiences larger fluctuations and is considered to be riskier than MSFT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RXRX	MSFT	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.74%	9.31%	+9.43%
Volatility (6M) Calculated over the trailing 6-month period	44.79%	22.14%	+22.65%
Volatility (1Y) Calculated over the trailing 1-year period	73.46%	24.92%	+48.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.46%	26.59%	+66.87%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	93.62%	27.03%	+66.59%

Dividends

RXRX vs. MSFT - Dividend Comparison

RXRX has not paid dividends to shareholders, while MSFT's dividend yield for the trailing twelve months is around 0.81%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MSFT Microsoft Corporation	0.81%	0.70%	0.73%	0.74%	1.06%	0.68%	0.94%	1.20%	1.69%	1.86%	2.37%	2.33%
RXRX Recursion Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both RXRX and MSFT in my portfolio?

RXRX and MSFT have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, RXRX or MSFT?

RXRX has higher volatility (18.74%) compared to MSFT (9.31%). In terms of maximum drawdown, RXRX dropped -93.13% vs MSFT's -69.38%.

Which has better risk-adjusted returns?

MSFT currently has the higher Sharpe Ratio (-0.15 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.